Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Geomerics Update

26 Mar 2012 07:00

RNS Number : 9988Z
Angle PLC
26 March 2012
 



For immediate release

26 March 2012

 

ANGLE plc

 

("ANGLE" or the "Company")

 

GEOMERICS EXPANDS PRODUCT RANGE AND SALES

 

 

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce positive progress in new products, sales and market recognition at its 33%-owned portfolio company Geomerics, which specialises in computer games middleware.

 

At the recent Game Developers Conference (GDC 2012) in San Francisco, Geomerics announced the development of new products for mobile devices and for Nintendo's new Wii™ U console. These new products significantly expand the addressable market for Geomerics products.

 

The company demonstrated a range of new technologies aimed at rounding out the Enlighten offering and getting 'next gen ready'. In partnership with ARM, they showcased Enlighten running smoothly on a Mali-based Samsung Galaxy Tab 7.7 tablet on the expo floor. This is an expansion of Geomerics' product capability and Enlighten, via ARM CPU, now supports a wide range of mobile devices including the iOS-based iPad and iPhone, Android devices and PlayStation® Vita, offering new sales opportunities.

 

Geomerics also announced its new product capability for Nintendo's new Wii™ U console, the successor to the highly successful Wii™ adding to its capability on the PC, PS3 and Xbox360. Geomerics also displayed on the NVIDIA and Intel booths at GDC 2012, reaffirming their commitment to high-end gaming experiences on the PC and console.

 

Geomerics sales continue to strengthen. Since GDC 2012 finished on 9th March, Geomerics has already been notified of four new sales for major new games, three of which are to entirely new customers, and its pipeline of prospective customers is steadily increasing.

 

Finally, there has been further market recognition for Geomerics' Enlighten with a BAFTA award being won by a computer game incorporating the Enlighten lighting solution.

 

The British Academy of Film and Television Arts (BAFTA) 2011 GAME Award has been awarded to Battlefield 3, an Electronic Arts game incorporating Enlighten. The GAME Award recognises the best game of the year, and is the only category at the British Academy Video Games Awards to be voted for by the general public.

 

Battlefield 3 is the fastest selling Electronic Arts game ever, selling more than 5 million units in its first week of release. Enlighten is the only real-time global illumination solution available for computer games, enabling the lighting to be realistically calculated in real-time as the player interacts with the game environment and other players. As a result, Enlighten provides a much more realistic player experience.

 

The reviews of Battlefield 3 have frequently singled out the lighting. For example The Guardian reported "Visually Battlefield 3 is a marvel of beautiful lighting effects" and GameSpy in its review said "Once they see the light - they'll understand what a special game Battlefield 3 is". The quality of the lighting and graphics in general has been a major contributor to the success of the game.

 

In a first time win at the BAFTA awards for the Battlefield franchise, it beat titles including FIFA 12, The Elder Scrolls V: Skyrim and Batman: Arkham City. Also, for the first time Battlefield beat the long-standing favourite Call of Duty, which has dominated the GAME Award for the past three years.

 

 

Gary Lewis, Chief Executive of Geomerics, commented:

"The BAFTA award for Battlefield 3 is an excellent further endorsement of the success of the game. We are pleased with ongoing adoption of the Enlighten technology in major new games. 2012 looks like being a great year for us and the expansion into mobile computing offers substantial growth potential for the future."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are delighted by Geomerics' ongoing success and believe the company is positioned well for the future."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQXLFLLXFFBBL
Date   Source Headline
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.